Fernanda Arnaldez Email & Phone Number

Washington, Dc, Us

Cambridge, Cambridgeshire, Gb

My teams are responsible for the development of immunotherapy biologics, T-cell engagers, small molecules, cell therapy and antibody-drug conjugate assets within the Early Oncology Research and Development Organization, from candidate lead selection to phase III-enabling clinical trials. I am responsible and accountable for strategy, development and execution of the portfolio across multiple line functions.

Cambridge, Cambridgeshire, Gb

I lead a group within the Early Oncology R&D organization that is responsible for the development (lead selection to phase III enabling studies) of Immunotherapy, Cell Therapy and ADC early assets. I am responsible and accountable for strategy, development and execution of the portfolio across line functions.

Dallas, Texas, Us

The Osteosarcoma Institute (OSI) is a 501(c)(3) public, non-operating foundation, with the mission of identifying and funding most promising and breakthrough osteosarcoma clinical trials and science.

New York, Ny, Us

Chief is a private network built to drive more women into positions of power and keep them there. Chief is the only organization specifically designed for senior women leaders to strengthen their leadership journey, cross-pollinate ideas across industries, and effect change from the top-down.

Baltimore, Maryland, Us

July 2023 - Aug 2024 : Vice Chair, Executive CommitteeThe Board of Advisors provides valuable advice and support to the campus leadership and to University System of Maryland, in order to succeed in its mission and grow in its ability to serve students and the community.

Rockville, Md, Us

As Executive Medical Director, accountable to the CMO, I provided leadership and medical support to meet the company strategic goals, establishing critical cross-functional relationships with diverse line functions including Regulatory Affairs, Clinical Operations and CROs, Biostatistics/Data Management, R&D and others. - Global Program Leader, Breast Cancer anti-HER-2 franchise (Fc-optimized mAb); leading to the regulatory approval of Margenza (margetuximab) in December 2020 and commercial launch in March 2021.- Global Program Leader, B7-H3 Franchise (Fc-Optimized mAbs, mAbs, bi-specifics, ADCs) - including partnerships with Asia-Pacific industry collaboratorsDesign, development and implementation of clinical studies from first in human through proof of concept and pivotal/registrational trials, regulatory interactions, stakeholder management.

Bethesda, Md, Us

As its Scientific Officer, I held the responsibility of portfolio management, operations, grants and contracts of a complex infrastructure of more than forty high-performing North American sites that form the Experimental Therapeutics Clinical Trials Network (ETCTN).The objectives of the ETCTN are to:• Conduct clinical trials of NCI-IND agents in high priority areas of unmet medical needs• Ensure efficient and timely activation and conduct of these clinical trials• Integrate preclinical findings using clinical samples for biomarker analysis• Promote collaboration among institutions and investigators• Integrate molecular characterization, pharmacology, cancer biology, and imaging into clinical trials

Bethesda, Md, Us

-Designed and implemented innovative clinical trials, with the goal of improving outcomes for children, adolescents and young adults with solid tumors and genetic tumor predisposition syndromes. -Led care of high-acuity oncology patients receiving state-of-the-art therapies, including stem cell transplant, cell therapies (CAR-T cells, NK-cell based therapies, modified TCRs), anti-tumor vaccines, immunotherapy, targeted chemotherapy and others. - Director, NIH Pediatric and Wild-Type GIST Program

Bethesda, Md, Us

The Cancer Therapy Evaluation Program (CTEP) coordinates the clinical therapeutics development program of the Division of Cancer Treatment and Diagnosis (DCTD), NCI. -Led and coordinated a vast national network of 12 Lead Academic NCI-designated cancer centers and 41 organizations; coordinating multiple stakeholders: pharmaceutical collaborators, biotechnology companies, Government agencies and academic organizations-Chair, NCI Community Oncology Research Program (NCORP) Tissue Procurement Study - Cancer Moonshot Initiative-Program Director, Experimental Therapeutics Clinical Trials Network (ETCTN)-Protocol Review Committee, CTEP

Bethesda, Md, Us

Basel, Baselstadt, Ch

Global Medical Lead, Registrational Phase III Study, Pasireotide (leading to approval)

Basel, Baselstadt, Ch

Bethesda, Md, Us

Designed and led the first clinical trial exploiting the unique biology of SDH deficient /wild-type gastrointestinal stromal tumors Delivered state-of the-art clinical care to high-acuity patients on experimental therapies, such as gene therapy, cell therapy, and drugs in a first-in-human contextContributed to physician education programs.In my laboratory, I led cross-functional programs with the goal of applying biological discoveries in rhabdomyosarcoma and Ewing’s sarcoma to therapeutic target and compound selection. This included but was not limited to loss-of-function high throughput screening, functional genomics and chemical screens.

Bethesda, Md, Us

Bethesda, Md, Us

Baltimore, Md, Us

Pediatric Hematology-Oncology Fellow and Chief FellowJohns Hopkins University/National Cancer Institute- National Institutes of Health

Pittsburgh, Pennsylvania, Us

Pediatric Residency Program

Md, Medicine

Mba: Biopharma Innovation

Senior Leadership Program - Dhhs

Certificate In Business Excellence, -- Focus On: Corporate Governance, Financial Accounting, And Digital Health

Executive Certificates In Management, Leadership, Finance, Macroeconomics And Ai, -- Focus On: Artificial Intelligence, Business Strategy, Finance And Macroeconomics